Targeting CLIC6 with theaflavin enhances radiotherapy sensitivity in ER+/HER2− breast cancer
This study identified CLIC6 as a novel gene associated with radioresistance in ER<sup>+</sup>/HER2<sup>-</sup> breast cancer and showed that theaflavin functions as a natural radiosensitizer in a CLIC6-dependent manner, consistent with its high-affinity interaction with CLIC6. Targeting CLIC6 may provide a promising strategy to enhance radiotherapy efficacy in this common breast cancer subtype.
Authors
- Tiantian She
- Mengying Suo (ORCID: https://orcid.org/0000-0002-6639-9996)
- Chong Chen (ORCID: https://orcid.org/0000-0002-6787-0495)
- Lin Liu
Institutions
- Nankai University (CN)
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tcr-2025-aw-2466
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00